Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
about
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisOral disease-modifying therapies for multiple sclerosis.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisSafety of teriflunomide for the management of relapsing-remitting multiple sclerosis.Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.
P2860
Q26777686-D234D58B-22BD-493C-ACDD-D4A0DCC889C4Q28082878-712AB00D-F694-4EE8-8E6E-152B6958BC4EQ34996562-0AC7613A-5C4E-4AAE-AD21-524C3D6E897EQ36484448-2D5841C5-FD07-4459-B8D1-04EA6942AD84Q38357590-1748D8CA-C86A-40DD-8721-071714F13516Q38661416-BF9E6F45-CA76-4441-BF73-9A1435BC22BAQ47868767-F1C684A9-D970-4744-84E1-10E45F6EE1DA
P2860
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
@en
type
label
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
@en
prefLabel
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
@en
P2093
P2860
P1476
Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
@en
P2093
Arianna Sartori
Dawn Carle
Mark S Freedman
P2860
P304
P356
10.1517/14656566.2014.902936
P407
P577
2014-04-17T00:00:00Z